Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer

Share this content:
Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer

Sponsors and Collaborators
Columbia University
Celgene Corporation

Contact
Sam Cammack
212-305-1207
ac2239@columbia.edu

Principal Investigator
James M McKiernan, MD, Columbia University Medical Center, Urology

ClinicalTrials.gov Identifier
NCT00583349

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters